title: Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.
abstract: The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients >/=the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher beta(2)-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients >/=60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT >12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.
authors.affiliation: Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: D E
authors.initials: DE
authors.lastname: Reece
authors.forename: C
authors.initials: C
authors.lastname: Bredeson
authors.forename: W S
authors.initials: WS
authors.lastname: Pérez
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: M J
authors.initials: MJ
authors.lastname: Zhang
authors.forename: K K
authors.initials: KK
authors.lastname: Ballen
authors.forename: G J
authors.initials: GJ
authors.lastname: Elfenbein
authors.forename: C O
authors.initials: CO
authors.lastname: Freytes
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.forename: M A
authors.initials: MA
authors.lastname: Gertz
authors.forename: J
authors.initials: J
authors.lastname: Gibson
authors.forename: S A
authors.initials: SA
authors.lastname: Giralt
authors.forename: A
authors.initials: A
authors.lastname: Keating
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: D
authors.initials: D
authors.lastname: Maharaj
authors.forename: D
authors.initials: D
authors.lastname: Marcellus
authors.forename: P L
authors.initials: PL
authors.lastname: McCarthy
authors.forename: G A
authors.initials: GA
authors.lastname: Milone
authors.forename: S D
authors.initials: SD
authors.lastname: Nimer
authors.forename: S
authors.initials: S
authors.lastname: Pavlovsky
authors.forename: L B
authors.initials: LB
authors.lastname: To
authors.forename: D J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
authors.forename: J R
authors.initials: JR
authors.lastname: Wingard
authors.forename: D H
authors.initials: DH
authors.lastname: Vesole
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D009656:North America; D010014:Osteolysis / Q000209:etiology; D036102:Peripheral Blood Stem Cell Transplantation / Q000401:mortality / Q000706:statistics & numerical data; D012042:Registries; D012189:Retrospective Studies; D013020:South America; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome